Myocardial infarction (MI) in mice results in cardiac rupture at 4-7 days post-MI, whereas cardiac fibrosis and dysfunction occur later. Ac-SDKP has anti-inflammatory, anti-fibrotic, and pro-angiogenic properties. We hypothesized that Ac-SDKP reduces cardiac rupture and adverse cardiac remodeling, and improves function by promoting angiogenesis and inhibiting detrimental reactive fibrosis and inflammation after MI. C57BL/6J mice were subjected to MI and treated with Ac-SDKP (1.6 mg/kg/day) for 1 or 5 weeks. We analyzed: 1) intercellular adhesion molecule-1 (ICAM-1) expression; 2) inflammatory cell infiltration and angiogenesis; 3) gelatinolytic activity; 4) incidence of cardiac rupture; 5) p53, the endoplasmic reticulum (ER) stress marker C...
Persistent ventricular remodeling following myocardial ischemia/reperfusion (MI/R) injury results in...
A key feature of acute myocardial infarction (AMI) is an alteration in cardiac architecture. Signali...
The cell-permeant peptide inhibitor of MAPKAP kinase 2 (MK2), MMI-0100, inhibits MK2 and downstream ...
Myocardial infarction (MI) in mice results in cardiac rupture at 4-7 days post-MI, whereas cardiac f...
Myocardial infarction (MI) in mice results in cardiac rupture at 4-7 days post-MI, whereas cardiac f...
Myocardial infarction (MI) in mice results in cardiac rupture at 4-7 days post-MI, whereas cardiac f...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
Myocarditis is commonly associated with cardiotropic infections and has been linked to development o...
Objective N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a potent natural inhibitor of hematopoi...
Objective N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a potent natural inhibitor of hematopoi...
Persistent ventricular remodeling following myocardial ischemia/reperfusion (MI/R) injury results in...
A key feature of acute myocardial infarction (AMI) is an alteration in cardiac architecture. Signali...
The cell-permeant peptide inhibitor of MAPKAP kinase 2 (MK2), MMI-0100, inhibits MK2 and downstream ...
Myocardial infarction (MI) in mice results in cardiac rupture at 4-7 days post-MI, whereas cardiac f...
Myocardial infarction (MI) in mice results in cardiac rupture at 4-7 days post-MI, whereas cardiac f...
Myocardial infarction (MI) in mice results in cardiac rupture at 4-7 days post-MI, whereas cardiac f...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
The natural peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) decreases inflammation in chroni...
Myocarditis is commonly associated with cardiotropic infections and has been linked to development o...
Objective N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a potent natural inhibitor of hematopoi...
Objective N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a potent natural inhibitor of hematopoi...
Persistent ventricular remodeling following myocardial ischemia/reperfusion (MI/R) injury results in...
A key feature of acute myocardial infarction (AMI) is an alteration in cardiac architecture. Signali...
The cell-permeant peptide inhibitor of MAPKAP kinase 2 (MK2), MMI-0100, inhibits MK2 and downstream ...